As of 2025-09-17, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -51.68 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.03 CAD, the upside of Briacell Therapeutics Corp is -568.51%.
Based on its market price of 11.03 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 568.51%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -51.68 - -51.68 | -51.68 | -568.51% |
| DDM - Stable | (71.88) - (226.85) | (149.36) | -1454.2% |
| DDM - Multi | (16.16) - (40.60) | (23.23) | -310.6% |
| Market Cap (mil) | 20.74 |
| Beta | 3.23 |
| Outstanding shares (mil) | 1.88 |
| Enterprise Value (mil) | 15.72 |
| Market risk premium | 5.10% |
| Cost of Equity | 11.08% |
| Cost of Debt | 5.00% |
| WACC | 7.39% |